Overview of Imine

What is Imine? (Imipramine)

Property	Description
Active ingredient	Imipramine hydrochloride
Form	Tablet, Capsule, Injectable Solution
Pharmacological class	Tricyclic Antidepressant (TCA)
General purpose	Mood stabilization and emotional balance
Origin	Synthetic compound

What Type of Medicine is Imine and What is Its Active Ingredient?

The medicine Imine is a prescription-only medicine that belongs to the Tricyclic Antidepressant (TCA) class, utilizing Imipramine hydrochloride as its active ingredient. Imipramine is chemically characterized as a Non-selective Monoamine Reuptake Inhibitor, placing it among the category of first-generation antidepressants. This classification is characterized by its dual action on key brain chemicals.

This synthetic compound is recognized for its foundational role in psychopharmacology, distinguishing it structurally from newer antidepressant classes. Imipramine is a drug used to affect brain chemistry and function. Popular brands containing this formulation include Tofranil and Janimine.

What Does It Mean That Imine is a Dibenzazepine Derivative?

The classification of Imipramine as a Dibenzazepine derivative refers to its specific core chemical structure, a defining characteristic of this group of drugs. Imine is available in several pharmaceutical preparations to allow for different routes of administration, primarily as a tablet, capsule, and a solution for intramuscular injection. The availability of the injectable solution is a notable feature, often reserved for clinical situations where prompt initial action is needed.

What is the General Purpose of Imipramine’s Mechanism?

The general purpose of Imipramine is the modulation of mood and the stabilization of emotional balance, which is achieved through its mechanism of affecting neurochemistry. Imipramine acts by influencing the availability of two key neurotransmitters, serotonin and norepinephrine, in the brain by slowing their reabsorption (reuptake) into nerve cells. Imipramine is one of the oldest antidepressants with recognized efficacy in modulating these neurotransmitters. This means the drug helps stabilize emotional state by adjusting the brain's chemical signaling balance, a process associated with the ability to normalize emotional regulation.

Regulatory References

What side effects are possible with Imine?

Possible Side Effects and Safety Information

The safety profile of Imine (Imipramine) is extensively categorized in official regulatory documentation, which defines possible adverse reactions by frequency and affected organ system. This information is intended to communicate the officially documented risks associated with the medicine.

Frequency-Classified Adverse Reactions

The most commonly documented effects are classified as Very Common or Common in regulatory labeling. Very Common adverse reactions include anticholinergic effects like dry mouth, as well as somnolence (drowsiness), dizziness, and tremor. Cardiovascular effects such as sinus tachycardia and orthostatic hypotension are also frequently documented. Common reactions often involve the gastrointestinal system (constipation, nausea), general effects (headache, fatigue), and weight changes (increased appetite and weight gain).

Serious Adverse Reactions and System-Organ Classes

The label documents rare but serious adverse events, notably involving the Cardiac and Blood and Lymphatic System Disorders. These include cardiac arrhythmias (such as QTc prolongation and Torsade de pointes), and severe blood conditions like agranulocytosis and leukopenia. Seizures and severe hepatobiliary reactions (cholestatic jaundice, hepatitis) are also documented as rare occurrences. Effects on the Nervous System, Psychiatric System, and Vascular System are officially listed safety domains.

Population-Specific Safety Notes

Official safety documents indicate that older adults are particularly susceptible to certain adverse effects, including confusion, orthostatic hypotension, and severe cardiac events. For the pediatric and young adult population (under 25), the label notes the risk of emergent suicidal thinking and behavior, especially during the initial months of therapy or following dose changes. Safety notes also state that use is restricted during the acute recovery period following a recent myocardial infarction.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Imine (Imipramine) is officially documented as a serious and potentially fatal event, with deaths having been reported. Given the potential for rapid onset of severe toxicity, patients must seek immediate medical attention for any suspected overingestion, regardless of the amount.

Documented Overdose Manifestations

Official regulatory information emphasizes the risk of both cardiac and nervous system toxicity. Signs and symptoms can develop rapidly and include critical effects such as Cardiac Dysrhythmias (irregular heartbeats), Severe Hypotension (very low blood pressure), and Convulsions (Seizures). Other documented central nervous system effects include Coma, Restlessness, Agitation, and Delirium. The development of a potentially life-threatening Serotonin Syndrome has also been reported in official labeling.

Urgent Actions and Management

Regulators mandate that all patients, especially children, who may have ingested an overdose must be hospitalized and kept under close surveillance due to the drug’s potential for instability. Treatment is described as symptomatic and supportive, as there is no specific antidote officially listed. Continuous ECG monitoring in an intensive care setting is recommended and should be maintained for several days after cardiac rhythm stabilization.

Population Considerations

Regulatory documents note that children are more sensitive to acute overdosage, and any ingestion by infants or young children must be considered serious. Specific effects like confusional states with hallucinations are also noted as a risk, particularly in the elderly.

Therapeutic Uses of Imine

What Imine Treats: Main Uses and Benefits

The therapeutic scope of Imine generally focuses on providing symptomatic relief across several key medical domains, ranging from addressing symptoms related to systemic imbalance to managing specific types of chronic discomfort and functional issues.

The medicine is commonly used to help with depression and is relevant for easing nocturnal enuresis in children, alongside other common uses in psychiatric care. Its benefit provides support that helps ease the overall symptom burden and may assist with maintaining functional stability when symptoms are more noticeable.

Imine is relevant across conditions characterized by episodic or fluctuating symptom patterns, including major depressive disorder, panic disorder, certain forms of neuropathic pain stemming from nerve damage, and persistent nighttime bedwetting in the appropriate pediatric age group.

“This medication is considered relevant when symptoms become more noticeable, offering supportive relief that helps patients cope more steadily.”

The medication is relevant in contexts involving heightened systemic burden that involve acute or unstable symptom patterns, such as severe depressive episodes or the recurrence of sudden panic attacks, where supportive symptom management is appropriate. It helps address symptom clusters that may become intense or disruptive, contributes to easing the overall symptom load during symptomatic periods, and supports the management of functional, involuntary control issues in specialized pediatric care.

Quick Fact: Relief for Chronic Neurogenic Discomfort and Involuntary Control Issues

Regulatory References

NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

The eligibility for using Imine (Imipramine) is defined by official regulatory documents, strictly prohibiting use in certain populations.

Populations for Whom Use is Contraindicated

Classification	Prohibited Groups
Absolute Contraindications	Recent Myocardial Infarction (acute recovery phase), concurrent use of a Monoamine Oxidase Inhibitor (MAOI), and documented hypersensitivity to imipramine or other dibenzazepine TCAs.
Specific Comorbidities	Individuals with severe liver disease, uncontrolled narrow-angle glaucoma, or Mania/unstable Bipolar Disorder.

Age-Related Eligibility and Restrictions

Use is approved for adults for psychiatric conditions. For children, use is not recommended for psychiatric conditions but is approved for nocturnal enuresis in those 6 years of age and older. Use in older adults (geq65 years) is established but requires caution due to increased cardiovascular risk.

Conditional Use and Physiological Status

Use is restricted and requires caution in patients with pre-existing cardiac disease, seizure disorders, renal or hepatic impairment, or conditions that increase the risk of urinary retention. Imine is not recommended during pregnancy or while breastfeeding, as the medicine is excreted into human milk.

What should I know about interactions with other medicines?

The official regulatory profile for Imine establishes specific constraints on co-administration with other medicines and products. The profile is defined by formal contraindicated combinations and documented changes to drug exposure or effect.

Co-administration with Monoamine Oxidase Inhibitors (MAOIs), including Linezolid and intravenous Methylene Blue, is strictly prohibited due to the risk of severe pharmacodynamic potentiation. Regulatory guidelines mandate a minimum 14-day washout period when switching between Imine and an MAOI used for psychiatric treatment. Formal restrictions also apply to Pimozide and Thioridazine.

Imine's systemic exposure is affected by metabolic interactions. Medicines that inhibit the CYP2D6 enzyme (such as Fluoxetine or Cimetidine) may increase plasma concentrations of Imine, a key pharmacokinetic interaction documented in labeling. Conversely, hepatic enzyme inducers (like Phenytoin or Barbiturates) may decrease Imine levels. Individuals identified as CYP2D6 Poor Metabolizers are also noted in official labeling to have higher Imine plasma concentrations.

Pharmacodynamic augmentation is noted with other CNS Depressants, including alcohol, which can enhance the depressant effects. Serotonergic agents and the herbal product St. John's Wort may increase the risk of an additive serotonergic effect. Additionally, Tobacco smoking is documented to increase Imine's clearance, potentially reducing systemic exposure.

Mechanism of Action

The drug Imine exerts its mechanistic action by engaging specific molecular targets to modulate biological activity within dysregulated pathways. Its mechanism involves receptor- and enzyme-mediated signaling, leading to changes in pathway dynamics.

Receptor-Mediated Signaling Modulation

Imine functions as an agonist or antagonist at specific neurotransmitter receptors in the central and peripheral nervous systems. By precisely adjusting the activity of these receptors, Imine modifies the intensity of signals, resulting in modulation of activity within overactive neuronal or physiological pathways.

Enzyme Inhibition and Pathway Regulation

The drug acts as an inhibitor or modulator of key enzymes involved in cascades that produce or degrade specific signaling mediators. This direct engagement modifies the overall concentration and duration of action of these mediators, which modifies the effect profile of excessive mediator concentration and facilitates an adjustment of activity within the targeted pathways.

Influencing Downstream Mechanistic Cascades

Imine initiates or suppresses signaling sequences downstream of its primary binding events. This influence on subsequent molecular steps modulates feedback loops within the affected biological systems, leading to a re-establishment of pathway dynamics.

Dosage and Administration Information

Imine (Imipramine) is administered primarily via the oral route, available in tablet, capsule, and solution forms. An intramuscular injection is also an approved route, generally reserved for acute clinical situations where immediate action is needed. The medication can be taken with or without food.

Official Dosing and Scheduling

The standard adult dosing regimen for outpatients typically begins at 75 mg daily, with a usual maintenance range between 50 mg and 150 mg per day. The maximum dose for outpatient use is generally limited to 200 mg per day. In hospitalized settings, the daily dosage may be increased up to a maximum of 300 mg under close supervision. Dosing frequency is flexible, often administered once daily at bedtime to support adherence, or given in divided doses throughout the day.

Population-Specific Use Rules

Specific populations require defined dosage adjustments. For older adults (geriatric), treatment is initiated at a lower daily amount, such as 25 mg to 50 mg, and the maximum recommended dose is restricted to 100 mg per day. In pediatric use for nocturnal enuresis, the total daily dose is strictly weight-based and must not exceed 2.5 mg/kg. Furthermore, treatment for this specific indication is typically limited to a course duration that does not exceed three months.

Procedural Administration

Oral forms, particularly tablets, must be swallowed whole to ensure proper release characteristics. When discontinuing therapy, the dosage is typically tapered off gradually to avoid discontinuation-related symptoms or recurrence.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Imine (Imipramine)

This section summarizes the published evidence base and the types of clinical studies that was studied for Imine, focusing only on what the studies explored and what remains uncertain.

Evidence for Use in Major Depressive Disorder (MDD)

The research base for Imine in MDD is well-documented, consisting mainly of short-term randomized controlled trials (RCTs) and numerous meta-analyses that explored how symptoms change over time.

Research primarily examined adult patients, including those with a higher severity of depressive symptoms. The studies monitored outcomes related to systemic or functional imbalance using standardized scales. Findings describe patterns observed in the studies where measurements of symptom severity showed differences compared to the placebo groups in the acute phase of treatment.

What remains uncertain is the longevity of the observations, as the follow-up durations were limited in many of the core acute trials, meaning long-term effects are not fully established.

Evidence for Use in Nocturnal Enuresis (Childhood Bedwetting)

Imine was studied for its application in conditions associated with functional limitations, specifically persistent nighttime bedwetting in children.

Research consists of short-term randomized controlled trials applied in studies examining episodic or acute changes in the pediatric population. The trials examined objective study measures, such as the frequency of nocturnal events, and studies explored the rate of achieving sustained dryness during the treatment phase.

Research Limitations: Evidence is limited regarding the durability of the observations once treatment ends. Authoritative systematic reviews indicate that the evidence quality varies across studies due to variability in methodology in many older trials.

Long-Term Studies and Durability of Observations

Research has explored the long-term patterns of Imine use primarily in the context of maintenance treatment for depression and in monitoring recurrence rates for nocturnal enuresis. However, for most indications, the core evidence is derived from short-term randomized trials that do not fully characterize the long-term patterns of change.

Quality of Evidence and Areas of Uncertainty

The available evidence contributes to the broader evidence landscape but is marked by known limitations. The evidence quality varies across studies due to the age of some foundational trials. There is limited information for long-term outcomes across several indications, and findings were mixed or inconsistent in certain areas, such as the evidence for neuropathic pain. Research provides context but not individual predictions.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Imine (FAQ)

Q: Is Imine considered a long-term or short-term treatment?

Imine is typically described in official documents as a long-term maintenance treatment for conditions such as depression. However, for specific uses like nocturnal enuresis (bedwetting), the medication is generally indicated as a short-term treatment.

Q: Can Imine be used for conditions other than its main approved use?

The official regulatory profile for Imine defines the specific conditions for which the medicine has been studied and approved, which include Major Depressive Disorder and nocturnal enuresis. The regulatory labeling for the product is based only on the officially defined indications and does not describe use for other conditions.

Q: How long does it usually take to feel the effects of Imine?

For the treatment of depression, patient-focused information indicates that it may take some time before the full benefits are noticed. It is described that a period of up to one to two months may be needed to experience the medicine's maximum effect.

Q: If I miss a dose of Imine, what generally happens?

Patient information states that a missed dose is generally taken as soon as remembered. However, if it is close to the next dose, the missed dose is typically skipped, as official guidance states to avoid taking double doses.

Q: Is Imine related to or does it affect blood sugar levels?

Official labeling documents report that Imine can potentially influence blood sugar levels. Both the elevation and the lowering of blood sugar levels have been observed as possible effects associated with the use of this medicine.

Q: How is Imine handled by the body (e.g., is it cleared by the kidney)?

According to the official pharmacology information, Imine is mainly processed and metabolized by the liver. The medicine and its breakdown products are then primarily eliminated from the body through excretion in the urine.

Q: What kind of warnings are on the official label for Imine?

The official label includes a boxed warning (the most serious type of warning) concerning certain risks. This warning alerts users to the increased risk of suicidal thoughts and behavior in children, adolescents, and young adults (up to age 24) when starting treatment or following a dose change.

Q: Does Imine affect fertility in men or women?

The official safety information documents certain adverse reactions related to sexual function. This includes reports of changes in sexual drive or ability as a possible side effect of the medicine.

Q: Why do some people say they need to take Imine with food?

The official prescribing information for Imine states that the medicine may be taken either with or without food. While the label states it can be taken with or without food, taking it alongside food is a non-clinical practice that may help to minimize mild stomach upset.

Q: What are the signs that Imine might not be right for someone?

Official documents describe certain conditions and reactions that would make continued use unsafe. These include the new appearance or worsening of suicidal thoughts, a severe allergic reaction, or being in the acute recovery period following a recent heart attack.

Q: Are there any tests needed before starting Imine?

Official labeling indicates that an ECG (electrocardiogram) recording is described as a consideration prior to starting higher-than-usual doses of the medicine. Official documents also note that patients with existing heart disease are described as needing cardiac monitoring.

Q: Do older adults need to take a lower dose of Imine?

Yes. The official dosing instructions for specific populations specify that treatment for older adults should begin at a lower dose than for younger adults. Furthermore, the maximum recommended daily dose is restricted for the older adult population.

Q: What if a known side effect doesn't go away?

The official safety information classifies and documents certain adverse events that are considered serious. Examples of such effects include a severe rash or yellowing of the skin or eyes (jaundice). The presence of these serious effects is described in official documents as warranting immediate medical evaluation.

Q: How does Imine affect mood or energy levels?

The general purpose of the medicine's mechanism is described as the modulation of mood and the stabilization of emotional balance. However, the official safety profile lists sedation (drowsiness) as a very common adverse reaction, which can influence energy levels.

Q: Are there alternatives to Imine listed in medical guides?

Imine belongs to the class of tricyclic antidepressants (TCAs). Official medical resources and clinical guides often reference other classes of antidepressant medicines as potential alternatives to TCAs.

Q: What is the meaning of the black box warning on Imine's label?

The Black Box Warning is the most serious type of warning required by regulatory bodies. For Imine, it specifically alerts users to the increased risk of suicidal thoughts and behavior in individuals under 25 when starting treatment or following dose changes.

Q: Can Imine make an underlying condition worse?

Official documents list certain psychiatric conditions as contraindications because Imine may worsen them. For example, Imine is contraindicated in individuals with Mania or unstable Bipolar Disorder, and its use may activate psychosis in schizophrenic patients.

Q: What if I stop taking Imine suddenly?

Official instructions state that the dosage is to be tapered off gradually when ending therapy. This is a procedural mandate to avoid the risk of discontinuation-related symptoms or the recurrence of the underlying condition.

Q: Are there any lifestyle changes that official sources suggest when taking Imine?

Official patient information notes warnings concerning limiting alcohol intake, as it can enhance the depressant effects of the medicine. It is also noted that tobacco smoking is documented to increase the medicine's clearance, and avoiding excessive sun exposure is often suggested due to possible skin photosensitization.

Q: What is the difference between Imine and a generic version of Imine?

Regulatory requirements ensure that the active ingredient, imipramine hydrochloride, is the same in both the brand-name and generic versions of the medicine. Both forms contain the same amount of the active ingredient and use the same route of administration.

Q: Does Imine have known interactions with common painkillers like ibuprofen?

Official documents describe a documented drug interaction where co-administration with NSAIDs (such as ibuprofen) has been associated with an increased risk of abnormal bleeding. This is a common warning for drugs within this class.

Q: Does Imine have any known effects on sleep?

The official safety profile documents effects on the central nervous system. Common adverse reactions include both drowsiness (somnolence) and, conversely, insomnia (trouble sleeping).

Q: What should I do if I accidentally take too much Imine?

The factual procedure outlined in patient instructions for suspected over-ingestion is described as contacting a poison control center or seeking emergency medical attention.

Q: Is Imine addictive or habit-forming?

The official label includes a section on abuse and dependence. While it is not typically described as addictive, official labeling notes that the requirement to gradually taper the dose upon discontinuation is described as avoiding discontinuation symptoms.

Q: What if I have an allergic reaction to Imine?

Signs of a severe reaction (hypersensitivity) are documented in the official safety profile. These symptoms, such as a severe rash or yellowing of the skin or eyes, are described in official documents as warranting immediate medical evaluation.

How should Imine be stored and disposed of?

Official Storage and Disposal Instructions

The regulatory profile for Imine (Imipramine) mandates specific storage and disposal practices to maintain the product's stability and ensure safety.

Storage Requirement	Rule as Documented in Official Labeling
Temperature	Store at controlled room temperature, between 20 C to 25 C (68 F to 77 F).
Protection	Keep from freezing; protect from excessive heat, moisture, and direct light.
Packaging	Keep the medicine in a tightly closed, original container and dispense with a child-resistant closure.
Stability Note	Discoloration may indicate a loss of potency; the oral solution has a 30-day stability limit once opened.

Child-Safety Storage: The product must be stored out of the sight and reach of children.

Disposal Mandates: Unused or expired Imine must not be flushed down the toilet or placed in the drain. Disposal must follow official methods, such as utilizing a community drug take-back program.

Imine